SCHEMBL22553710

SCHEMBL22553710

CC(C)(C)OC(=O)N1CCN(c2ccnc3c2ccn3COCC[Si](C)(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.42
GPR119 Q8TDV5 7/20 0.40
GRIA1 P42261 1/20 0.39
IDE P14735 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
DTYMK P23919 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
WNT3A P56704 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18440881 0.83 HTR1A (0.36)
SCHEMBL21632536 0.82 FAAH (0.44) GPR119
SCHEMBL21632467 0.82 GPR119 (0.46) ACHEGPR119
SCHEMBL29776666 0.81 IDE (0.38) ACHEGPR119GRIA1IDEMEN1
SCHEMBL20919958 0.81 IDE (0.38) ACHEGPR119GRIA1IDEMEN1
SCHEMBL38662235 0.81 ACHE (0.40) ACHEGPR119POLBCKS1BSKP1
SCHEMBL30501939 0.79 GPR119 (0.40) ACHEGPR119GRIA1SMN1; SMN2MEN1
SCHEMBL22735031 0.79 GPR119 (0.40) ACHEGPR119GRIA1SMN1; SMN2MEN1
SCHEMBL20183873 0.78 GPR119 (0.51) GPR119
SCHEMBL24997692 0.77 SMN1; SMN2 (0.46) ACHEGPR119SMN1; SMN2MEN1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111566102-B Substituted pyrrolopyridines as activin receptor-like kinase inhibitors 缆图药品公司 2023-09-08 CN disclosed
EP-3697786-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2022-08-31 EP disclosed
US-11236086-B2 Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2022-02-01 US disclosed
US-20200331908-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2020-10-22 US disclosed
CN-111566102-A Substituted pyrrolopyridines as activin receptor-like kinase inhibitors 缆图药品公司 2020-08-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236086-B2 Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase ALK, ACVR1, ACVR2A ACHE 4682/4885GPR119 1944/4885GRIA1 1893/4885
US-20200331908-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ALK, ACVR1, ACVR2A ACHE 4682/4885GPR119 1944/4885GRIA1 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.